<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01013779</url>
  </required_header>
  <id_info>
    <org_study_id>TROG 09.03</org_study_id>
    <secondary_id>ACTRN12610000480088</secondary_id>
    <nct_id>NCT01013779</nct_id>
  </id_info>
  <brief_title>Merkel Positron Emission Tomography (PET) Protocol</brief_title>
  <acronym>MP3</acronym>
  <official_title>A Phase II Efficacy Study of Chemo-Radiotherapy in PET Stage II and III Merkel Cell Carcinoma of the Skin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trans Tasman Radiation Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trans Tasman Radiation Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase II Study designed to evaluate the efficacy of Chemo-Radiotherapy in achieving&#xD;
      loco-regional control in patients with Merkel Cell Carcinoma (MCC) of the skin. Patients will&#xD;
      undergo PET scans to assist in staging and planning the patient's treatment as well as&#xD;
      assessing response at the conclusion of treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to loco-regional failure curve</measure>
    <time_frame>Minimum of 18 months follow up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of grade 3 and 4 toxicity and incidence of febrile neutropenia</measure>
    <time_frame>Duration of Radiotherapy treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival and time to distant failure curves</measure>
    <time_frame>3 year acturarial curves</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients for which PET can influence management.</measure>
    <time_frame>12 weeks post Radiotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive Predictive Value (PPV) and Negative Predictive Value (NPV) of PET.</measure>
    <time_frame>12 weeks post Radiotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment PET complete response rate for patients with unresected disease</measure>
    <time_frame>12 weeks post Radiotherapy</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Merkel Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional radical radiotherapy in this trial means that those patients with microscopic disease receive a dose of 50Gy using daily incremental fractions of 2Gy over 25 fractions and those with macroscopic disease receive 54Gy in 27 fractions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>During radiotherapy: Carboplatin (AUC2) commences on day 1 of radiation and is repeated at weekly intervals on days 8, 15, 22 and 29 (of radiation).&#xD;
After radiotherapy: 3 weeks after completing radiotherapy, 3 cycles of 3 weekly carboplatin (AUC4.5) intravenously on day 1.</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>After Radiotherapy: 3 weeks after completing the radiation therapy, 3 cycles of 3 weekly etoposide (80mg/M2/day) intravenously days 1-3</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Microscopic Disease: 50Gy delivered in 2Gy doses over 25 fractions&#xD;
Macroscopic Disease: 54Gy delivered in 2Gy doses over 27 fractions</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>RT</other_name>
    <other_name>Radiation Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Trial Registration:&#xD;
&#xD;
        Patients may be registered on the trial only if they meet all of the following criteria:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Written informed consent to participate in the study&#xD;
&#xD;
          -  Able to undergo 18-FDG PET scan (no uncontrolled diabetes mellitus or severe&#xD;
             claustrophobia).&#xD;
&#xD;
          -  Available for follow-up.&#xD;
&#xD;
          -  Using adequate contraception if capable of child bearing&#xD;
&#xD;
          -  Any Merkel Cell carcinoma confined to the primary and/or nodal sites&#xD;
&#xD;
          -  ECOG 0-2.&#xD;
&#xD;
          -  Full Blood Count (FBC) should be satisfactory ( Haemoglobin &gt; or equal to 10g/dl,&#xD;
             neutrophils &gt; or equal to 2.0 x 109 /l and platelets &gt; or equal to 100 x 109 /l) and&#xD;
             renal function (GFR &gt; or equal to 50 ml/min) and hepatic function ( ALT &lt; 5 X upper&#xD;
             limit normal, bilirubin &lt; 1.5 X upper limit normal)&#xD;
&#xD;
          -  Patients must be able to tolerate protocol treatment&#xD;
&#xD;
        Exclusion Criteria for Registration:&#xD;
&#xD;
          -  Previous chemotherapy in the past 5 years or prior radiotherapy to the area of concern&#xD;
&#xD;
          -  Unable to comply with treatment protocol eg dementia&#xD;
&#xD;
          -  Other malignancy in the past 5 years other than non-melanoma skin cancer.&#xD;
&#xD;
          -  Women who are pregnant or lactating.&#xD;
&#xD;
          -  Clinical evidence of metastatic disease.&#xD;
&#xD;
          -  Immunosuppression from long term steroid use or immunosuppressive drugs.&#xD;
&#xD;
          -  Any serious illness or medical condition that precludes the safe administration of the&#xD;
             chemotherapy including:&#xD;
&#xD;
               1. Active infection&#xD;
&#xD;
               2. Uncontrolled or unstable cardiac disease including unstable angina, myocardial&#xD;
                  infarction within the last 3 months, and recurrent ventricular arrhythmias&#xD;
&#xD;
        Inclusion Criteria for Treatment Registration:&#xD;
&#xD;
        Patients may proceed to protocol treatment if they meet the following criteria:&#xD;
&#xD;
          -  High risk disease with no evidence of distant spread: Biopsy proven MCC with a primary&#xD;
             that is &gt; 2cm (T2N0M0= Stage II) and/or regional nodes (any T, N1M0= Stage III); OR&#xD;
             Recurrent MCC not previously treated with radiation treatment; Dermal or in-transit&#xD;
             metastasis with or without nodes; Occult primary with involved nodes&#xD;
&#xD;
          -  Patients who have no metastases on CT or PET scan OR If CT is suggestive of&#xD;
             metastases, they must be PET negative&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Poulsen</last_name>
    <role>Study Chair</role>
    <affiliation>Trans Tasman Radiation Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Campbelltown</name>
      <address>
        <city>Campbelltown</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Calvary Mater Newcastle</name>
      <address>
        <city>Waratah</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiation Oncology Services - Mater Centre</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital Radiation Oncology</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Research Australia</name>
      <address>
        <city>Toowoomba</city>
        <state>Queensland</state>
        <zip>4350</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesis Cancer Care (previously Premion)</name>
      <address>
        <city>Tugun</city>
        <state>Queensland</state>
        <zip>4224</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geelong Hospital</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>http://www.trog.com.au</url>
    <description>please visit this website for further trial specific information</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 12, 2009</study_first_submitted>
  <study_first_submitted_qc>November 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2009</study_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Merkel Cell Cancer</keyword>
  <keyword>PET scanning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Merkel Cell</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

